cellbas
system
use
discov
antivir
agent
dissect
viral
life
cycl
particularli
earli
entri
stage
allow
mechanist
approach
identifi
evalu
antivir
agent
target
specif
step
viral
entri
report
method
examin
viral
inactiv
viral
attach
viral
entryfus
antivir
assay
purpos
describ
use
hepat
c
viru
model
assay
use
discov
novel
antagonistsinhibitor
earli
viral
entri
help
expand
scope
candid
antivir
agent
drug
develop
video
compon
articl
found
viral
infect
constant
threat
public
health
signific
caus
epidem
diseas
morbid
death
worldwid
specif
mode
control
viral
infect
includ
vaccin
develop
antivir
therapi
vaccin
effort
proven
success
immun
sever
virus
mani
viral
pathogen
remain
without
protect
vaccin
includ
dengu
viru
denv
human
cytomegaloviru
hcmv
hepat
c
viru
hcv
human
immunodefici
viru
hiv
respiratori
syncyti
viru
rsv
antivir
hand
play
import
role
manag
viral
infect
prophylact
vaccin
unavail
howev
date
licens
costeffect
antivir
drug
avail
compar
number
viral
pathogen
threaten
public
health
importantli
due
increas
global
travel
rapid
urban
situat
aggrav
risk
epidem
outbreak
emergingreemerg
viral
infect
introduc
nonindigen
area
recent
outbreak
caus
sever
acut
respiratori
syndrom
sar
viru
influenza
virus
denv
west
nile
viru
wnv
measl
viru
mv
middl
east
respiratori
syndrom
mer
viru
ebola
viru
among
exampl
reflect
need
antivir
develop
immun
andor
therapeut
unavail
addit
alway
potenti
risk
gener
drugresist
infect
current
use
antivir
thu
continu
develop
expans
scope
antivir
emergingreemerg
viral
infect
necessari
provid
better
manag
strategi
safeguard
public
health
antivir
therapi
consist
direct
act
antivir
daa
target
specif
viral
protein
cofactor
mediat
import
step
viral
life
cycl
exampl
nucleosid
analogu
acyclovir
inhibit
herpesviru
dna
polymeras
proteas
inhibitor
boceprevir
telaprevir
antagon
hcv
oseltamivir
zanamivir
neuraminidas
inhibitor
block
releas
influenza
viru
particl
infect
cell
howev
licens
viral
entri
inhibitor
includ
enfuvirtid
target
hiv
prevent
fusion
maraviroc
block
hiv
coreceptor
therebi
prevent
viral
entri
explor
novel
antagonistsinhibitor
viral
entri
could
help
provid
addit
therapeut
prophylact
therapeut
use
combin
antivir
differ
mechan
action
better
manag
viral
infect
identif
antivir
involv
structureguid
drug
design
candid
drug
screeningbas
strategi
method
assess
antivir
activ
test
agent
includ
biochem
assay
enzymat
activ
evalu
cellbas
system
cellbas
system
viral
life
cycl
dissect
distinct
stage
infect
entri
event
attach
fusion
uncoat
replic
phase
viral
genom
replic
protein
translat
virion
egress
assembl
matur
releas
sinc
assay
adapt
investig
specif
stage
use
variou
tool
method
approach
allow
identificationexamin
potenti
candid
antivir
specif
mechan
action
target
distinct
stage
analyz
instanc
analyz
drug
effect
specif
free
viru
particl
prior
bind
host
cell
viral
inactiv
assay
perform
assay
viru
allow
incub
test
drug
dilut
titrat
drug
infect
cell
monolay
addit
step
viral
attach
entryfus
stage
also
analyz
individu
shift
temperatur
infect
mani
envelop
virus
viral
entryfus
host
cell
membran
greatli
facilit
typic
preclud
affect
viru
bind
final
use
report
virus
cell
system
could
facilit
studi
permit
highthroughput
analysi
previous
employ
cellbas
approach
dissect
earli
entri
variou
envelop
virus
examin
antivir
compound
potenti
antagon
viral
entri
herein
variou
method
use
includ
viral
inactiv
viral
attach
viral
entryfus
assay
describ
note
ensur
procedur
involv
cell
cultur
viru
infect
conduct
certifi
biosafeti
hood
appropri
biosafeti
level
sampl
handl
purpos
describ
protocol
gaussia
luciferas
reportertag
hcv
use
model
viru
context
repres
result
compound
chebulag
acid
chla
punicalagin
pug
use
candid
antivir
target
viral
glycoprotein
interact
cell
surfac
glycosaminoglycan
earli
viral
entri
step
heparin
known
interfer
entri
mani
virus
use
posit
control
treatment
context
basic
background
virolog
techniqu
propag
virus
determin
viru
titer
express
infecti
dose
plaqu
form
unit
pfu
focu
form
unit
ffu
multipl
infect
moi
reader
refer
refer
prior
exampl
optim
condit
use
virus
shown
repres
result
reader
refer
refer
well
detail
list
tabl
figur
twice
add
assay
solut
xttbase
vitro
toxicolog
assay
kit
well
incub
plate
anoth
hr
allow
xtt
formazan
product
determin
absorb
micropl
reader
test
wavelength
nm
refer
wavelength
nm
calcul
percentag
surviv
cell
use
follow
formula
cell
viabil
refer
absorb
test
compound
solvent
control
ex
dmso
treatment
respect
determin
concentr
cellular
cytotox
cc
test
compound
analyt
softwar
graphpad
prism
accord
manufactur
protocol
note
readout
viral
infect
depend
viru
system
use
involv
method
plaqu
assay
measur
report
signal
reportertag
virus
method
detect
reporterhcv
infect
base
luciferas
report
activ
describ
collect
supernat
infect
well
clarifi
x
g
microcentrifug
min
mix
test
supernat
luciferas
substrat
gaussia
luciferas
assay
kit
directli
measur
luminomet
accord
manufactur
instruct
express
hcv
infect
log
rel
light
unit
rlu
determin
viral
inhibit
calcul
effect
concentr
ec
test
compound
hcv
infect
use
algorithm
graphpad
prism
softwar
accord
manufactur
protocol
note
exampl
incub
period
viral
dose
variou
virus
list
figur
higher
concentr
viru
also
test
increas
moipfu
therefor
requir
dilut
virusdrug
mixtur
accomplish
ml
basal
medium
cell
cultur
medium
fb
note
dilut
subtherapeut
concentr
prevent
signific
interact
test
compound
host
cell
surfac
allow
examin
treatment
effect
cellfre
virion
note
dilut
depend
antivir
dose
respons
test
compound
particular
viral
infect
determin
prior
perform
particular
assay
comparison
mix
viru
test
compound
immedi
dilut
incub
period
subtherapeut
concentr
prior
infect
figur
shortterm
add
dilut
hcvdrug
mixtur
onto
cell
monolay
amount
viru
x
ffu
final
moi
incub
hr
allow
viral
adsorpt
follow
infect
remov
dilut
inocula
gentli
wash
well
pb
twice
note
perform
wash
gentli
avoid
lift
cell
appli
basal
medium
well
incub
hr
analyz
result
infect
assay
supernat
luciferas
activ
describ
readout
viral
infect
note
exampl
incub
period
viral
dose
variou
virus
list
figur
attach
higher
concentr
viru
also
test
increas
moipfu
note
perform
wash
gentli
avoid
lift
cell
appli
basal
medium
well
incub
hr
analyz
result
infect
assay
supernat
luciferas
activ
describ
readout
viral
infect
figur
viral
inactiv
assay
perform
examin
whether
two
specif
natur
compound
chla
pug
could
inactiv
differ
envelop
virus
cellfre
state
prevent
subsequ
infect
cytotox
antivir
dose
respons
compound
determin
prior
perform
mechanist
studi
virus
pretreat
test
compound
virusdrug
mixtur
dilut
subtherapeut
concentr
inocul
onto
respect
cell
monolay
viru
system
shown
figur
chla
pug
appear
interact
cellfre
virion
result
irrevers
effect
protect
cell
monolay
subsequ
infect
two
test
compound
achiev
near
inhibit
hcmv
hcv
wherea
octob
page
block
observ
mv
rsv
result
suggest
chla
pug
direct
impact
free
viru
particl
inactiv
neutral
infect
figur
attach
entryfus
assay
carri
explor
effect
chla
pug
earli
viral
entryrel
event
hcmv
hcv
mv
rsv
chla
pug
effect
prevent
bind
investig
virus
onto
respect
host
cell
shown
inhibit
result
viral
infect
figur
attach
light
gray
bar
inhibitori
effect
viru
attach
compound
similar
hcmv
figur
hcv
figur
figur
rsv
figur
rang
hand
pug
appear
effect
chla
mv
bind
figur
inhibit
rate
two
compound
vari
control
treatment
heparin
known
block
entri
mani
virus
also
inhibit
attach
hcmv
rsv
ad
mv
less
effici
hcv
ensu
viral
entryfus
assay
examin
whether
chla
pug
retain
activ
viru
entryfus
phase
figur
entryfus
dark
gray
bar
chla
pug
observ
effect
impair
viral
entryfus
step
virus
examin
figur
f
yield
protect
effect
respect
cell
monolay
heparin
also
potent
inhibit
entryfus
rsv
infect
less
efficaci
hcmv
hcv
mv
inhibit
averag
report
method
identifi
evalu
antivir
compound
base
mechanist
approach
dissect
earli
viral
entri
event
describ
specif
assay
allow
us
examin
effect
test
compound
free
viru
particl
viral
attach
viral
entryfus
critic
step
implement
distinctli
evalu
drug
effect
specif
stage
earli
viral
entri
instanc
viral
inactiv
assay
dilut
virusdrug
mixtur
subtherapeut
concentr
prevent
signific
interact
test
compound
host
cell
surfac
titrat
drug
ensur
inhibitori
effect
observ
subsequ
infect
host
cell
due
direct
interact
test
compound
cellfre
virion
rather
effect
test
compound
host
cell
membran
membraneassoci
molecul
includ
viral
receptor
similarli
shift
temperatur
allow
viru
bind
entri
facilit
viru
entryfus
viral
attach
assay
viral
entryfus
assay
crucial
determin
test
compound
effect
specif
event
feasibl
due
temperatur
sensit
envelop
virus
step
infect
issu
import
consider
decid
whether
candid
agent
valu
continu
subsequ
phase
drug
develop
similarli
earli
viral
entryspecif
assay
describ
report
allow
examin
drug
effect
distinct
viral
entri
stage
cellular
level
specif
context
authent
viral
infect
vitro
result
obtain
assay
would
therefor
help
better
predict
antivir
efficaci
test
compound
also
identifi
potenti
unwant
offtarget
effect
host
cell
one
potenti
limit
though
vitro
cellbas
assay
may
complet
reflect
actual
vivo
entri
step
context
natur
viral
infect
nonetheless
assay
present
protocol
serv
analyt
platform
mechanismbas
identif
evalu
novel
antivir
agent
develop
report
virus
report
cell
system
quantit
amount
viral
infect
greatli
facilit
cellbas
screen
evalu
antivir
compound
exampl
includ
use
recombin
virus
carri
report
gene
mean
recombin
human
cell
line
contain
report
gene
driven
specif
viru
promot
report
infect
luciferasetag
hcv
easili
monitor
quantit
report
signal
thu
facilit
data
analysi
incorpor
use
reporterbas
tool
earli
viral
entri
assay
describ
essenti
adapt
highthroughput
format
mechanismbas
screen
small
molecul
librari
conclus
protocol
describ
assay
dissect
earli
viral
entri
mean
identifi
evalu
mechanismspecif
antivir
compound
assay
would
use
discov
novel
antagonistsinhibitor
viral
entri
help
expand
scope
antivir
agent
develop
prophylact
andor
therapeut
treatment
author
declar
compet
interest
exist
